Toyota|$18.16 (¥2,904)+2.11%▲ (in JPY terms)
Sony|$22.75 (¥3,638)-0.84%▼ (in JPY terms)
SoftBank|$52.65 (¥8,418)-2.48%▼ (in JPY terms)
MUFG|$19.66 (¥3,143)+3.18%▲ (in JPY terms)
Keyence|$505.42 (¥80,810)+3.15%▲ (in JPY terms)
Nintendo|$46.43 (¥7,424)-0.03%▼ (in JPY terms)
NTT|$0.93 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.66 (¥4,743)-2.21%▼ (in JPY terms)
Tokyo Electron|$382.58 (¥61,170)+13.89%▲ (in JPY terms)
Recruit|$67.92 (¥10,860)+0.14%▲ (in JPY terms)
ITOCHU|$11.61 (¥1,857)-0.03%▼ (in JPY terms)
Honda|$9.45 (¥1,512)+8.98%▲ (in JPY terms)
Shin-Etsu|$48.76 (¥7,796)+4.32%▲ (in JPY terms)
Tokio Marine|$44.36 (¥7,092)+0.65%▲ (in JPY terms)
Fast Retailing|$494.47 (¥79,060)-0.78%▼ (in JPY terms)
Toyota|$18.16 (¥2,904)+2.11%▲ (in JPY terms)
Sony|$22.75 (¥3,638)-0.84%▼ (in JPY terms)
SoftBank|$52.65 (¥8,418)-2.48%▼ (in JPY terms)
MUFG|$19.66 (¥3,143)+3.18%▲ (in JPY terms)
Keyence|$505.42 (¥80,810)+3.15%▲ (in JPY terms)
Nintendo|$46.43 (¥7,424)-0.03%▼ (in JPY terms)
NTT|$0.93 (¥148)+0.00%▲ (in JPY terms)
Takeda|$29.66 (¥4,743)-2.21%▼ (in JPY terms)
Tokyo Electron|$382.58 (¥61,170)+13.89%▲ (in JPY terms)
Recruit|$67.92 (¥10,860)+0.14%▲ (in JPY terms)
ITOCHU|$11.61 (¥1,857)-0.03%▼ (in JPY terms)
Honda|$9.45 (¥1,512)+8.98%▲ (in JPY terms)
Shin-Etsu|$48.76 (¥7,796)+4.32%▲ (in JPY terms)
Tokio Marine|$44.36 (¥7,092)+0.65%▲ (in JPY terms)
Fast Retailing|$494.47 (¥79,060)-0.78%▼ (in JPY terms)

Astellas Pharma Inc.

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-unsuitable resectable muscle-invasive bladder cancer.”

by

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorizat … 続きを読む

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an additional indication for the antibody-drug conjugate Padsev™ (enfortumab vedotin) in combination with pembrolizumab for the treatment of muscle-invasive bladder cancer for which cisplatin is indicated.”

by

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an addition … 続きを読む

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab, regardless of whether cisplatin is indicated, as a neoadjuvant therapy for muscle-invasive bladder cancer, and has granted it priority review.”

by

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug c … 続きを読む

Contact